Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Island Pharmaceuticals Ltd ( (AU:ILA) ).
Island Pharmaceuticals Ltd has secured a Master Service Agreement with Texas Biomedical Research Institute, a leading BSL-4 facility in the USA, to advance the development of its antiviral candidate, Galidesivir. This agreement enables potential non-human primate studies crucial for the FDA’s Animal Rule development pathway, following positive FDA engagement confirming eligibility and potential for a Priority Review Voucher post-approval. The collaboration with Texas Biomed, known for its expertise in high-containment infectious disease research, is a strategic move to progress Galidesivir towards FDA approval, while the company continues to seek additional research partners.
More about Island Pharmaceuticals Ltd
Island Pharmaceuticals Ltd is an Australian company specializing in antiviral drug development. The company focuses on creating solutions for high-consequence viral threats with no approved treatments, aligning with US government preparedness priorities.
Average Trading Volume: 730,351
Technical Sentiment Signal: Buy
Current Market Cap: A$122.4M
See more insights into ILA stock on TipRanks’ Stock Analysis page.